Partnership Targets Oat Supply Challenges Bon Natural Life Limited (NASDAQ: BON) and China Oat Group Co., Ltd. have unveiled the BON Natural Ingredients and Biomanufacturing Joint Laboratory, a collaboration announced at a symposium in Xi'an on November 20, 2026. The lab aims to develop biomanufacturing technologies for high-value oat-derived natural ingredients. BON's subsidiary, Xi'an App-Chem Bio (Tech) Co., Ltd., will co-operate the facility alongside China Oat Group, which supplies oat-based health products to markets with strong demand but constrained by limited raw material availability and high production costs.
Synthetic Biology and AI at Core The integrated innovation framework spans the full value chain, from fundamental research and pilot-scale development to standards-setting and industrial commercialization. The lab will employ synthetic biology as its technological foundation and artificial intelligence as a competitive differentiator. Oats contain bioactive compounds including beta-glucan and avenanthramides (AVAs), which research has linked to cardiovascular protection, blood glucose regulation, antioxidant effects, and anti-inflammatory properties. Through the joint lab, BON and China Oat Group aim to develop biomanufacturing technologies that address supply availability, stability, and production costs.
Standards Development as Priority The partners have identified standards development as critical to commercialization.
The lab will conduct systematic testing and validation of ingredient purity, safety, and elemental and isotopic profiles to establish differentiated quality standards that approximate naturally derived counterparts. China Oat Group holds more than ten invention patents in China and multiple patents in the United States, Europe, Canada, and Australia. The company has developed expertise in oat protein enzymatic hydrolysis and beta-glucan bioactivity preservation. BON Chairman Yongwei Hu stated: "Our strategic collaboration with China Oat Group marks a pivotal step in our efforts to establish a stronger presence in the core natural ingredients sector, accelerate our expansion into the rapidly growing global biomanufacturing market, and further strengthen our position as an innovation leader in the industry. Through the Joint Lab, we aim to advance cutting-edge research in areas such as the biosynthesis of high-value natural ingredients, the discovery of functional bioactive compounds, and precision nutrition interventions. We are committed to accelerating the commercialization of scientific and technological innovations and delivering a broader range of safe and effective health solutions to consumers."
Why It Matters
The partnership addresses a supply-side bottleneck in the natural ingredients market.
By applying synthetic biology and AI to oat-derived bioactives, the lab could lower production costs and increase consistency—critical factors for scaling health ingredient products across food, supplement, and personal care channels.
For more insights and trends in the food and beverage sector, check out more articles in The Food & Beverage Magazine family of publications.
Written by FBM Publications Editors